---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-102673"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:09.710049+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715

## Summary
- CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.
- CFO Daniel Schneiderman base salary increased to $391,000; target bonus at 40%.
- Stock options granted: CEO 493,341 shares, CFO 317,266, employees 352,266 total.
- Board Chair annual cash compensation reduced from $100K to $35K; consulting fees cut to $1/quarter.
- Non-employee directors each receive 42,913 share options; Prof. Steinman gets one-time 200,000 share option.

## SEC filing metadata
- accession: 0001213900-25-102673
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/0001213900-25-102673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/ea0262506-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-102673
- JSON: https://secwatch.observer/filing/0001213900-25-102673.json
- Plain text: https://secwatch.observer/filing/0001213900-25-102673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.